To the 4p brigade ..15 Jul 2020 10:15
""" The publication describes the first Moditope® vaccine, Modi-1, and its ability to stimulate potent T cell responses that translate into tumour protection in melanoma and ovarian cancer models. The responses were mediated by CD4 T cells and were also able to protect against a second challenge of the tumour confirming the induction of a memory response. """
1. Do you understand the value of just ovarian cancer ?
In 2012, new cases occurred in approximately 239,000 women.[3] In 2015 it was present in 1.2 million women and resulted in 161,100 deaths worldwide.[8][7] Among women it is the seventh-most common cancer and the eighth-most common cause of death from cancer.[3] The typical age of diagnosis is 63.[2] Death from ovarian cancer is more common in North America and Europe than in Africa and Asia.[3]
Immunotherapy progress in ovarian cancer is lagging behind that for other cancer types. So far, no PD-1/L1 agent is approved for the tough-to-treat tumor. Pfizer and Merck KGaA previously chalked up multiple failures for their anti-PD-L1 drug Bavencio in ovarian cancer, including in previously treated patients and in new patients.
Merck & Co.’s PD-1 king Keytruda showed limited benefit for women with advanced and recurrent ovarian cancer. According to results from the Keynote-100 trial, just unveiled at this year’s American Society of Clinical Oncology virtual meeting, solo Keytruda triggered a response in merely 8% of patients who had received between one and three prior lines of treatment.
https://www.fiercepharma.com/marketing/roche-s-attempt-for-tecentriq-at-ovarian-cancer-fails-avastin-pairing
Sign In
Follow the stocks
